Purdue Pharma, L.P.
One Stamford Forum
About Purdue Pharma, L.P.
Purdue Pharma L.P., headquartered in Stamford, CT, is a privately held pharmaceutical company founded by physicians and focused on meeting the needs of healthcare providers and the patients in their care. Together with its independent associated companies, Purdue is dedicated to finding, developing, and bringing to market new medicines and related products that improve health outcomes. The company has long been known for its pioneering research on persistent pain, a principal cause of human suffering.
Purdue also has a growing line of non-prescription products including laxatives, microbicides, and nutraceuticals. The company is dedicated to serving the evolving needs of healthcare providers, patients, and caregivers with prescription and non-prescription medicines. A commitment to innovation and caring spans every aspect of the organization, from discovering and launching new medicines to demonstrating their medical value.
Purdue has led the battle against inadequate treatment of pain by developing sustained-release medications to manage pain. Its sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to pain management.
In 1993, Purdue established Partners Against Pain® as a resource to help patients, caregivers, and healthcare professionals advance standards of pain care and alleviate unnecessary suffering through education and advocacy. Purdue has also assumed a leading role in addressing the serious public health problem of prescription drug abuse, supporting programs intended to help stem abuse.
At its research facilities in Cranbury, New Jersey, Purdue scientists are discovering new compounds to treat pain and developing formulations and delivery systems to help improve patient safety.
163 articles with Purdue Pharma, L.P.
Purdue, Bristol-Myers Squibb and Apotex have been singled out in opioid-related lawsuits in Canada.
Adlon Therapeutics L.P. to Provide Funding Opportunities for Research to Expand Understanding of ADHD
Company accepting proposals for investigator-initiated research to evaluate outcomes associated with certain assessments of ADHD, and explore the burden and impact of ADHD on adolescent and adult patients
Eisai and Purdue Pharma Announce Buy Out of Purdue's Rights in Worldwide Collaboration to Develop and Commercialize Lemborexant
Eisai Inc. and Purdue Pharma L.P. announced that Eisai will buy out Purdue's rights to the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer's Disease.
Eisai Co., Ltd has bought out Purdue Pharma L.P.'s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer Disease.
A new poll shows nearly two-thirds of people blame the pharmaceutical companies for the opioid crisis.
FDA Grants Competitive Generic Therapy (CGT) Designation to Purdue Pharma’s Investigational Nalmefene HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose
Committed to advancing solutions to the opioid addiction crisis, Purdue will not profit from nalmefene HCl
Attorneys for current and former directors of Purdue Pharma, including members of the Drs. Mortimer and Raymond Sackler families, have submitted Motions to Dismiss the misleading complaint filed against them by the Massachusetts Attorney General.
The Opioid Spoon Project Names Tufts University As First Recipient Of Their Virtual Spoon Drop Campaign Launch
Tufts University receives The Opioid Spoon Project's signature Opioid Spoon, "Virtually," for their on-going financial relationship with the founders of Purdue Pharmaceuticals
Statement of Dr. Mortimer and Dr. Raymond Sackler Families Regarding Purdue Pharma’s Settlement with State of Oklahoma
The Dr. Mortimer and Dr. Raymond Sackler families issued a statement in connection with Purdue Pharma’s settlement with the State of Oklahoma
Embattled Purdue Pharma has agreed to pay $270 million to settle a lawsuit brought against the company over the marketing of its opioid painkiller OxyContin, according to reports.
Falsified Data Forces Duke to Pay $112 Million Settlement, Other Universities Under Scrutiny as Well
3/26/2019Duke University has agreed to pay the U.S. government more than $112 million to settle allegations that a university-associated researcher falsified claims in order to obtain funding from the National Institutes of Health and other federal agencies.
FDA Grants Purdue Pharma’s Nalmefene HCl Injection Fast Track Designation for the Emergency Treatment of Known or Suspected Opioid Overdose
Committed to advancing solutions to the opioid public health crisis, Purdue will not profit from nalmefene HCl
With a major lawsuit in Oklahoma targeting Johnson & Johnson and Purdue Pharma’s involvement in the opioid epidemic starting in May, many of the legal documents are being released, with strategies and sometimes incendiary rhetoric coming to light.
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
A Prescription Drug User Fee Act (PDUFA) date is set for December 27, 2019.
Imbrium Therapeutics Announces Enrollment of the First Patient in Expansion Phase of Tinostamustine Trial in Patients with Difficult-to-Treat Blood Cancers
Each study arm will run separately, with results to be submitted for upcoming medical meetings.
As Purdue Pharma grapples with multiple lawsuits over its OxyContin pain killer, there are reports that the drugmaker is exploring bankruptcy as a legal defense mechanism.
Purdue Pharmaceuticals is seeking to dismiss a Massachusetts lawsuit filed by that state’s attorney general that has been highly critical of the company’s marketing of its opioid pain treatment OxyContin and has also placed blame on the company for 670 opioid-related deaths in the state since 2009.
Imbrium Therapeutics and TetraGenetics Announce Strategic Research Collaboration and License Option to Develop Novel Biologic Therapeutics for Pain
TetraGenetics to receive up to $25 million in upfront license and FTE payments; is eligible to receive total contingent payments up to $248 million plus royalties
Court Documents Show Purdue’s Richard Sackler Did Not Want to Correct Misinformation About Streng...
2/22/2019Court documents have shown how invested Richard Sackler was in the drive at Purdue Pharma to make OxyContin a success. A recent deposition that was unsealed has revealed just how far Sackler was willing to go.
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study at the Sleep Research Society's Conference: Advances in Sleep and Circadian Science
Six-month data show significant improvements in patient-reported measures of sleep onset and sleep maintenance for investigational agent lemborexant